Drug Trial Radar · NCT06588179
SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt
Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
58
Planned (sponsor's estimate)
Start
Oct 1, 2024
Primary completion
Oct 1, 2027
Study completion Oct 1, 2027
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-center, single-arm, phase Ib/II study, aimed at assessing the safety and efficacy of SHR-1501 in combination with SHR-2005 as treatment for patients with high-risk non-muscle invasive bladder cancer (HR NMIBC) which is not completely resectable by transurethral resection of bladder tumor (TURBt).
Conditions
- NMIBC
Interventions
SHR-1501+SHR-2005Drug
SHR-1501, instillation;SHR-2005, instillation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I : Incidence of dose limiting toxicities (DLTs)Time frame: From Day 1 to Day 21
- Phase I : RP2D(Recommended Phase 2 dose)Time frame: From Day 1 to 90 days after last dose
- Phase I : Incidence and severity of adverse events (AEs)Time frame: From Day 1 to 90 days after last dose
- Phase II : CR rate at 3 monthsTime frame: Approximately 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.